

Provided by:



## HIV Grand Rounds from the University of Pennsylvania School of Medicine 2023-2024

### Primary Cardiovascular Prevention for People with HIV in 2024: Implications of the REPRIEVE Trial HIV Grand Rounds from the University of Pennsylvania School of Medicine 2023-2024 - 6/13/2024

June 13, 2024

12:00 PM - 1:00 PM

#### Target Audience

This program has been designed for FAMILY MEDICINE, NEUROLOGY, OBSTETRICS AND GYNECOLOGY, PSYCHIATRY, INTERNAL MEDICINE, INTERNAL MEDICINE - Infectious Disease

#### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Describe how to apply in clinical practice approaches for preventing HIV infection and getting newly diagnosed patients rapidly into care
- 2 Discuss how to individualize ARV therapy for the treatment-naïve and treatment-experienced patients to support adherence and patient satisfaction
- 3 Describe how to manage various patient populations, such as the aging patient with HIV infection, including issues associated with cardiovascular and bone disease, PWIDs, and underserved populations
- 4 Discuss the basic science concepts involved with HIV and be able to apply those concepts to HIV therapeutics, epidemiology, and other issues involved in HIV patient care and HIV prevention

#### Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Discuss rates of CVD among PWH and key risk factors contributing to the development of CVD
- 2 Discuss the rationale of the REPRIEVE Trial, REPRIEVE's primary findings and their impact for the care of PWH globally
- 3 Describe the unique phenotype of CVD in PWH, novel mechanisms of CVD, and the effects of statins on plaque and key biomarkers

#### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is not approved for nursing contact hours

**Pharmacists:** This activity is not approved for pharmacy contact hours

For more information, please contact  
Rick Gordon  
(773) 368-3932  
rgordon@viraled.com

Check your transcript online at <https://upenn.cloud-cme.com>

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

**Acknowledgement of Commercial Support\*** Janssen Therapeutics, Division of Janssen Products, LP, ViiV Healthcare, Merck Sharp & Dohme Corp., Gilead Sciences, Inc.

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Katharine Bar, MD	Course Director	Consulting Fee-AbbVie, Inc. (Relationship has ended) - 11/28/2023
Ian Frank, MD	Course Director	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Gilead Sciences, Inc   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Johnson & Johnson   Consulting Fee-Gilead Sciences, Inc (Relationship has ended)   Consulting Fee-Merck & Co (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.- ViiV Healthcare   Grant or research support-Johnson & Johnson (Relationship has ended)   Grant or research support-Moderna (Relationship has ended)   Grant or research support-Sanofi Genzyme (Relationship has ended)   Grant or research support-Pfizer, Inc. (Relationship has ended)   Grant or research support-Moderna (Relationship has ended)   Consulting Fee-Moderna (Relationship has ended) - 12/11/2023
Rick Gordon, BS	Other Planning Committee Member	Nothing to disclose - 11/01/2023
Brian Boyle, MD	Other Planning Committee Member	Nothing to disclose - 11/02/2023

Florence Momplaisir, MD	Co-Director	Nothing to disclose - 01/15/2024
Steven Grinspoon, MD	Faculty	Grant or research support-Gilead Sciences, Inc  Grant or research support-ViiV Healthcare  Grant or research support-KOWA  Advisor-Theratechnologies (Relationship has ended) - 06/06/2024

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected